Pegvisomant therapy in pituitary gigantism: Successful treatment in a 12-year-old girl

European Journal of Endocrinology

Volumn 153, Issue 2, 2005, Pages 195-201

  Rix, Mariane ^a   Laurberg, P ^a   Hoejberg, A S ^a   Brock Jacobsen, B ^b  

^a AALBORG UNIVERSITY HOSPITAL   (Denmark)

^b ODENSE UNIVERSITY HOSPITAL   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

CABERGOLINE; DOPAMINE RECEPTOR STIMULATING AGENT; GROWTH HORMONE; OCTREOTIDE; PEGVISOMANT; PROLACTIN; SOMATOMEDIN C;

ARTICLE; CASE REPORT; CLINICAL FEATURE; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG SAFETY; FEMALE; GIGANTISM; GROWTH HORMONE RELEASE; HUMAN; HUMAN TISSUE; HYPOPHYSIS ADENOMA; LYMPHOCYTIC INFILTRATION; ORAL GLUCOSE TOLERANCE TEST; PRIORITY JOURNAL; SCHOOL CHILD; TREATMENT OUTCOME;

ADENOMA; BODY HEIGHT; CHILD; FEMALE; GIGANTISM; HUMAN GROWTH HORMONE; HUMANS; INSULIN-LIKE GROWTH FACTOR I; MAGNETIC RESONANCE IMAGING; PITUITARY NEOPLASMS; RECEPTORS, SOMATOTROPIN;

EID: 23844469498     PISSN: 08044643     EISSN: None     Source Type: Journal    
DOI: 10.1530/eje.1.01956     Document Type: Article

References (30)

1. Eugster EA & Pescovitz OH. Commentary: gigantism. Journal of Clinical Endocrinology and Metabolism 1999 84 4379-4384.
2. Kane LA, Leinung MC, Scheithauer BW, Bergstrahl EJ, Laws ER Jr, Groover RV, Kovacs K, Horvath E & Zimmerman D. Pituitary adenomas in childhood and adolescence. Journal of Clinical Endocrinology and Metabolism 1994 79 1135-1140.
3. Artese R, D'Osvoldo DH, Molocznik I, Benencia H, Oviedo J, Burdman JA & Basso A. Pituitary tumors in adolescents patients. Neurological Research 1998 20 415-417.
4. Abe T, Tara LA & Ludecke DK. Growth hormone-secreting pituitary adenomas in childhood and adolescence: features and results of transnasal surgery. Neurosurgery 1999 45 1-10.
5. Dyer EH, Civit T, Visot A, Delalande O & Derome P. Transsphenoidal surgery for pituitary adenomas in children. Neurosurgery 1994 34 207-212.
6. Kopchick JJ. Discovery and mechanism of action of pegvisomant. European Journal of Endocrinology 2003 148 S21-S25.
7. Stewart PM. Pegvisomant: an advance in clinical efficiacy in acromegaly. European Journal of Endocrinology 2003 148 S27-S32.
8. Trainer PJ, Drake WM, Katznelson L, Freda PU, Herman-Bonert V, Van der Lely AJ, Dimaraki EV, Stewart PM, Friend KE, Vance ML, Besser M & Scarlett JA. Treatment of acromegaly with growth hormone-receptor antagonist pegvisomant. New England Journal of Medicine 2000 342 1171-1177.
9. Van der Lely AJ, Hutson RK, Trainer P, Besser GM, Barkan AL, Katznelson L, Klibanski A, Herman-Bonert V, Melmed S, Lee Vance M, Freda PU, Stewart PM, Friend KE, Clemmons DR, Johansson G, Stavrou S, Cook DM, Phillips LS, Strasburger CJ, Hacker S, Zib KA, Davis RJ, Scarlett JA & Thorner MO. Long-term treatment of acromegaly with pegvisomant, a growth hormone receptor antagonist. Lancet 2001 358 1754-1759.
10. Chaler E, Belgorosky A, Marceiras M, Medioroz M & Rivarola MA. Between-assay differences in serum growth hormone (GH) measurements: importance in the diagnosis of GH deficiency in childhood. Clinical Chemistry 2001 47 1735-1738.
11. Juul A, Bang P, Hertel NT, Main K, Dalgaard P, Jørgensen K, Müller J, Hall K & Skakkebaek NE. Serum insulin-like growth factor-1 in 1030 healthy children, adolescents, and adults: relation to age, sex, stage of puberty, testicular size, and body mass index. Journal of Clinical Endocrinology and Metabolism 1994 78 744-752.
12. Gelber SJ, Heffez DS & Donohoue PA. Pituitary gigantism caused by growth hormone excess from infancy. Journal of Pediatrics 1992 120 931-934.
13. Blumberg DL, Sklar CA, David R, Rothenberg S & Bell J. Acromegaly in an infant. Pediatrics 1989 83 998-1002.
14. Schoof E, Dorr HG, Kiess W, Ludecke DK, Freitag E, Zindal V, Rascher W & Dotsch J. Five-year follow-up of a 13-year-old boy with pituitary adenoma causing gigantism - effect of octreotide therapy. Hormone Research 2004 61 184-189.
15. Minagawa M, Yasuda T, Someya T, Kohno Y, Saeki N & Hashimoto Y. Effects of octreotide infusion, surgery and estrogen on suppression of height increase and 20 K growth hormone ratio in a girl with gigantism due to a growth hormone-secreting macroadenoma. Hormone Research 2000 53 157-160.
16. Nanto-Salonen K, Koskinen P, Sonninen P & Toppari J. Suppression of GH secretion in pituitary gigantism by continuous subcutaneous octreotide in a pubertal boy. Acta Paediatrica 1999 88 29-33.
17. Ritzén EM, Wettrell G, Davies G & Grant DB. Management of pituitary gigantism. The role of bromocriptine and radiotherapy. Acta Pædiatrica Scandinavica 1985 74 807-814.
18. Zimmerman D, Young WF, Ebersold MJ, Scheithauer BW, Kovacs K, Horvath E, Whitaker MD, Eberhardt NL, Downs TR & Frohman LA. Congenital gigantism due to growth hormone-releasing hormone excess and pituitary hyperplasia with adenomatous transformation. Journal of Clinical Endocrinology and Metabolism 1993 76 216-222.
19. Moran A, Sylvia L, Kovacs K, Horvath E, Singer W, Sagman U, Reubi JC, Wilson CB, Larson R & Pescovitz OH. Gigantism due to pituitary mammosomatotroph hyperplasia. New England Journal of Medicine 1990 323 322-326.
20. McConnon JK, Smyth HS & Horvath E. A case of sparsely granulated growth hormone cell adenoma associated with lymphycytic hypophysitis. Journal of Endocrinological Investigation 1991 14 691-696.
21. Ayuk J, Stewert PM, Sheppard MC & European Sandostatin LAR Group. Efficacy of Sandostatin LAR (long-acting somatostatin analogue) is similar in patient with untreated acromegaly and in those previously treated with surgery and/or radiotherapy. Clinical Endocrinology 2004 60 375-381.
22. McKeage K, Cheer S & Wagstaff AJ. Octreoitide long-acting release (LAR): a review of its use in the management of acromegaly. Drugs 2003 62 2473-2499.
23. Bevan JS, Atkin SL, Atkinson AB, Bouloux PM, Hanna F, Harris PE, James RA, McConnell M, Roberts GA, Scanlon MF, Stewert PM, Teasdale E, Turner HE, Wass JA & Wardlaw JM. Primary medical therapy for acromegaly: an open, prospective, multicenter study of the effects of subcutaneous and intramuscular, slow-release octreotide on growth hormone, insuline-like growth factor-1, and tumor size. Journal of Clinical Endocrinology and Metabolism 2002 87 4554-4563.
24. Eastman RC, Gordon P, Glatstein E & Roth J. Radiation therapy of acromegaly. Endocrinology and Metabolism Clinics of North America 1992 21 693-712.
25. Barrande G, Pittino-Lungo M, Coste J, Ponvert D, Bertagna X, Luton JP & Bertherat J. Hormonal and metabolic effects of radiotherapy in acromegaly: long-term results in 128 patients followed in a single center. Journal of Clinical Endocrinology and Metabolism 2000 85 3779-3785.
26. van den Bergh AC, Schoorl MA, Dullaart RP, van der Vliet AM, Szabo BG, ter Weeme CA & Pott JW. Lack of radiation optic neuropathy in 72 patients treated for pituitary adenoma. Journal of Neuroophthalmology 2004 24 200-205.
27. Herman-Bonert VS, Zib K, Scarlett JA & Melmed S. Growth hormone receptor antagonist therapy in acromegalic patients resistant to somatostatin analogs. Journal of Clinical Endocrinology and Metabolism 2000 85 2958-2961.
28. Parkinson C, Kassem M, Heickendorff L, Flyvbjerg A & Trainer PJ. Pegvisomant-induced serum insulin-like growth factor-1 normalization in patients with acromegaly returns elevated markers of bone turnover to normal. Journal of Clinical Endocrinology and Metabolism 2003 88 5650-5655.
29. Jehle S, Reyes CM, Sundeen RE & Freda PU. Alternate-day administration of pegvisomant maintains normal serum insulin-like growth factor-1 levels in patients with acromegaly. Journal of Clinical Endocrinology and Metabolism 2005 90 1588-1593.
30. Drake WM, Rowles SV, Roberts ME, Fode FK, Besser GM, Monson JP & Trainer PJ. Insulin sensitivity and glucose tolerance improve in patients with acromegaly converted from depot octreoide to pegvisomant. European Journal of Endocrinology 2003 149 521-527.